MLYS

Mineralys Therapeutics, Inc. (MLYS) | Rumor.io

Mineralys Therapeutics

MLYS

Attention (50-day avg)0%

Attention rank (50-day avg)#1,133

Bullish sentiment (50-day avg)78%

Price to earnings ratio-11.2

Market capitalization2.3B

Earnings per share-4.36

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-154.7M

Social

What share of all stock conversation is about MLYS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% +0	0% 0

Sep 25

Mineralys Therapeutics, Inc. ($MLYS) has a PDUFA date approaching on December 22, which could lead to a rerating of the stock.
A director at Mineralys Therapeutics, Inc. sold $3.0M of stock at $28.81, but this is considered a normal transaction and not a cause for concern.
The stock is expected to perform well leading up to the PDUFA date, with a potential solid pre-PDUFA run possible if yields cool down.

Generated by AI

Sentiment

Of the messages about MLYS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	92.31% -7.69	96.84% +55.18	75.78% +4.46	85.82% +7.63
Bearish	7.69% +7.69	3.16% -55.18	24.22% -4.46	14.18% -7.63

Bullish· Sep 2

$MLYS has shown strong momentum, with a 90% increase in value after positive results from a competitor, suggesting it could capture a significant share of a large market.
The company's competitive advantage, potentially due to a slightly better efficacy profile, could lead to significant growth, with a market capitalization of around $2 billion currently undervalued.
$MLYS has a strong technical setup, with a volume surge, rising RSI, and a golden cross, indicating a potential breakout and a good time to watch the charts closely.

Bearish· Sep 3

The offering price of $25 is considered too high, with some investors calling it a "scam" and others noting that it's almost double the previous day's price.
The company's stock price has risen significantly, with some investors labeling it as "manipulated" and "insanely ridiculous" that the price has risen so much with no news.
Institutional support and underwriter backing are expected to prop up the stock price, making it difficult for bearish investors to succeed in their positions.

Generated by AI

Topics

Of the messages about MLYS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	95.24%	98.67%	98.08%
Earnings	0%	0%	0%	0.67%
Technical Analysis	0%	4.76%	1.33%	0.67%
Analysts	0%	0%	0%	0.41%
Controversies	0%	0%	0%	0.05%
Macro	0%	0%	0%	0.1%

Analysts· Mar 7

Analysts at Credit Suisse initiated coverage of Mineralys Therapeutics with an outperform rating and $40 price target, citing a large unmet need for resistant hypertension treatment and potential best-in-class data.
Analysts at Bank of America, Stifel, Guggenheim, Wells Fargo, Evercore ISI, and B of A Securities initiated coverage of Mineralys Therapeutics with buy, overweight, or outperform ratings and various price targets.
Analysts at Stifel and Bank of America initiated coverage of Mineralys Therapeutics with buy ratings and price targets of $45 and $39, respectively, while analysts at Guggenheim and Credit Suisse initiated coverage with buy and outperform ratings and price targets of $32 and $40, respectively.

Announcements· Sep 3

Mineralys Therapeutics, Inc. (MLYS) priced an upsized underwritten public offering of 9.8M shares at $25.50 each, raising ~$250M in gross proceeds.
Underwriters have a 30-day option to purchase up to 1.47M additional shares, increasing the potential proceeds.
MLYS shares dipped 4% to $27.72 in pre-market trading following the announcement.

Generated by AI

Community

Of the messages about MLYS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	76.19%	86.92%	91.47%	68.56%
Newcomers	23.81%	13.08%	8.53%	31.44%

Regulars· Sep 2

Following the strong momentum of $MLYS, which rose by 90% after AstraZeneca's ($AZN) results, the market cap of Mineralys Therapeutics, Inc. has reached ~$2B.
$MLYS's efficacy is better than $AZN's baxdrostat, with identical safety, and its market capitalization is 1/4 of $AZN's, with Phase 2 CDK data adding to its appeal.
The recent acquisition of $MLYS by AstraZeneca is a speculation, based on the idea that $MLYS's efficiency and lower market capitalization compared to $AZN could lead to a large acquisition.

Newcomers· May 18

Mineralys Therapeutics, Inc. ($MLYS) is presenting new data from the Phase 3 Launch-HTN trial of Lorundrostat at the ESH26 conference, highlighting its efficacy and safety profile.
$MLYS is considered a potential steal, with a current EV of $1.8b, just 6 months from approval, compared to CINC's $1.8b valuation 3 years prior to approval.
The FDA has approved Baxfendy, a new hypertension medication by Astrazeneca, which is expected to be a major product, potentially generating over $5 billion in annual sales.

Generated by AI

Why the latest lorundrostat data matters for Mineralys Therapeutics investors Mineralys Therapeutics (MLYS) is back on watch after the company flagged that long term efficacy and safety results from its Transform-HTN extension study of lorundrostat will feature in a late breaking session at the American Heart Association Scientific Sessions 2026. The latest lorundrostat update comes after a choppy stretch for Mineralys Therapeutics, with the share price falling 8.65% over the past week and...

1d agoYahoo Finance

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

RADNOR, Pa., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that, on September 21, 2026, the Compensation Committee of Mineralys’ Board of Directors granted an inducement stock option award cov

8d agoYahoo Finance UK

Mineralys Therapeutics director Karydas sells $85,740 in stock

12d agoInvesting.com

Also Discussed

Investors talking about MLYS also mention

#	Name	Attention
1	Edgewise Therapeutics Inc.EWTX	0%new
2	Crinetics Pharmaceuticals IncCRNX	0%new
3	Revolution Medicines, Inc.RVMD	0.01%-0.01
4	Kyverna Therapeutics, Inc.KYTX	0%0
5	Structure Therapeutics Inc. American Depositary SharesGPCR	0%new
6	MoonLake Immunotherapeutics Class A Ordinary SharesMLTX	0.01%+0
7	Legend Biotech Corporation ADRLEGN	0%+0
8	Grace Therapeutics, Inc.GRCE	0%new
9	BridgeBio Pharma Inc.BBIO	0%-0.02
10	Neurogene Inc.NGNE	0%0

Mineralys Therapeutics, Inc.

Healthcare
Biotechnology

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for diseases driven by dysregulated aldosterone. Its lead product candidate, lorundrostat, is an orally administered, highly selective aldosterone synthase inhibitor being studied for cardiorenal conditions such as hypertension, chronic kidney disease, and obstructive sleep apnea. Mineralys Therapeutics concentrates on the treatment of hypertension and related comorbidities, aiming to address patients who do not respond adequately to existing therapies. The company operates as a development-stage drugmaker with a pipeline centered on aldosterone-targeted treatment, combining clinical research, regulatory activity, and outsourced manufacturing and trial operations. Based in Radnor, Pennsylvania, Mineralys Therapeutics plays a specialized role in the biopharmaceutical market by advancing therapies for cardiometabolic and renal diseases with a focus on precision targeting of hormone-driven pathways.

Website

Location

150 N. Radnor Chester Road

Radnor, PA, 19087

United States

Social

What share of all stock conversation is about MLYS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% +0	0% 0

Sep 25

Mineralys Therapeutics, Inc. ($MLYS) has a PDUFA date approaching on December 22, which could lead to a rerating of the stock.
A director at Mineralys Therapeutics, Inc. sold $3.0M of stock at $28.81, but this is considered a normal transaction and not a cause for concern.
The stock is expected to perform well leading up to the PDUFA date, with a potential solid pre-PDUFA run possible if yields cool down.

Generated by AI

Sentiment

Of the messages about MLYS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	92.31% -7.69	96.84% +55.18	75.78% +4.46	85.82% +7.63
Bearish	7.69% +7.69	3.16% -55.18	24.22% -4.46	14.18% -7.63

Bullish· Sep 2

$MLYS has shown strong momentum, with a 90% increase in value after positive results from a competitor, suggesting it could capture a significant share of a large market.
The company's competitive advantage, potentially due to a slightly better efficacy profile, could lead to significant growth, with a market capitalization of around $2 billion currently undervalued.
$MLYS has a strong technical setup, with a volume surge, rising RSI, and a golden cross, indicating a potential breakout and a good time to watch the charts closely.

Bearish· Sep 3

The offering price of $25 is considered too high, with some investors calling it a "scam" and others noting that it's almost double the previous day's price.
The company's stock price has risen significantly, with some investors labeling it as "manipulated" and "insanely ridiculous" that the price has risen so much with no news.
Institutional support and underwriter backing are expected to prop up the stock price, making it difficult for bearish investors to succeed in their positions.

Generated by AI

Topics

Of the messages about MLYS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	95.24%	98.67%	98.08%
Earnings	0%	0%	0%	0.67%
Technical Analysis	0%	4.76%	1.33%	0.67%
Analysts	0%	0%	0%	0.41%
Controversies	0%	0%	0%	0.05%
Macro	0%	0%	0%	0.1%

Analysts· Mar 7

Analysts at Credit Suisse initiated coverage of Mineralys Therapeutics with an outperform rating and $40 price target, citing a large unmet need for resistant hypertension treatment and potential best-in-class data.
Analysts at Bank of America, Stifel, Guggenheim, Wells Fargo, Evercore ISI, and B of A Securities initiated coverage of Mineralys Therapeutics with buy, overweight, or outperform ratings and various price targets.
Analysts at Stifel and Bank of America initiated coverage of Mineralys Therapeutics with buy ratings and price targets of $45 and $39, respectively, while analysts at Guggenheim and Credit Suisse initiated coverage with buy and outperform ratings and price targets of $32 and $40, respectively.

Announcements· Sep 3

Mineralys Therapeutics, Inc. (MLYS) priced an upsized underwritten public offering of 9.8M shares at $25.50 each, raising ~$250M in gross proceeds.
Underwriters have a 30-day option to purchase up to 1.47M additional shares, increasing the potential proceeds.
MLYS shares dipped 4% to $27.72 in pre-market trading following the announcement.

Generated by AI

Community

Of the messages about MLYS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	76.19%	86.92%	91.47%	68.56%
Newcomers	23.81%	13.08%	8.53%	31.44%

Regulars· Sep 2

Following the strong momentum of $MLYS, which rose by 90% after AstraZeneca's ($AZN) results, the market cap of Mineralys Therapeutics, Inc. has reached ~$2B.
$MLYS's efficacy is better than $AZN's baxdrostat, with identical safety, and its market capitalization is 1/4 of $AZN's, with Phase 2 CDK data adding to its appeal.
The recent acquisition of $MLYS by AstraZeneca is a speculation, based on the idea that $MLYS's efficiency and lower market capitalization compared to $AZN could lead to a large acquisition.

Newcomers· May 18

Mineralys Therapeutics, Inc. ($MLYS) is presenting new data from the Phase 3 Launch-HTN trial of Lorundrostat at the ESH26 conference, highlighting its efficacy and safety profile.
$MLYS is considered a potential steal, with a current EV of $1.8b, just 6 months from approval, compared to CINC's $1.8b valuation 3 years prior to approval.
The FDA has approved Baxfendy, a new hypertension medication by Astrazeneca, which is expected to be a major product, potentially generating over $5 billion in annual sales.

Generated by AI

Mineralys Therapeutics

Social

Sep 25

Bullish· Sep 2

Bearish· Sep 3

Analysts· Mar 7

Announcements· Sep 3

Regulars· Sep 2

Newcomers· May 18

Mineralys Therapeutics (MLYS) Faces A Fresh Valuation Test On New Lorundrostat Data

Mineralys Therapeutics director sells $3 million in shares

Mineralys to present lorundrostat trial data at AHA meeting

Mineralys Therapeutics CCO Eric Warren sells $209k in stock

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Mineralys Therapeutics director Karydas sells $85,740 in stock

Also Discussed

Mineralys Therapeutics, Inc.

Company Information

Location

Mineralys Therapeutics (MLYS) Faces A Fresh Valuation Test On New Lorundrostat Data

Mineralys Therapeutics director sells $3 million in shares

Mineralys to present lorundrostat trial data at AHA meeting

Mineralys Therapeutics CCO Eric Warren sells $209k in stock

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Mineralys Therapeutics director Karydas sells $85,740 in stock

Also Discussed

Social

Sep 25

Bullish· Sep 2

Bearish· Sep 3

Analysts· Mar 7

Announcements· Sep 3

Regulars· Sep 2

Newcomers· May 18